Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
Immuno-Oncology and Technology · 2025-03 · 25 · 101040
DOI: 10.1016/j.iotech.2024.101040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immuno-Oncology and Technology, 2025-03. Verfasst von B E Nelson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a critical role in immunotherapy resistance, characterized by immune cell composition, regulatory factors, and tumor mutational burden. Intratumoral immunotherapy, involving direct injection of immune-activating agents into tumors, holds promise for converting immunologically 'cold' tumors into responsive 'hot' tumors. This review explores the rationale for combining intratumoral therapies (ITs) with ICIs, highlighting their complementary mechanisms of action and clinical effects. Notable IT approaches include oncolytic viruses, toll-like receptor agonists, and stimulator of interferon gene agonists with ICIs. Overall, combining ITs with ICIs offers a rational strategy to potentiate antitumor immune response and overcome resistance. Further research is needed to optimize the combination strategies, identify biomarkers of response, and establish the safety and efficacy of these novel therapeutic approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.
- Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Nelson, B. E., Naing, A., Fu, S., Sheth, R. A., Murthy, R., & Piha-Paul, S. (2025). Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics. Immuno-Oncology and Technology, 25, 101040. https://doi.org/10.1016/j.iotech.2024.101040
Vancouver
Nelson BE, Naing A, Fu S, Sheth RA, Murthy R, Piha-Paul S. Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics. Immuno-Oncology and Technology. 2025;25:101040. doi:10.1016/j.iotech.2024.101040
BibTeX
@article{Nelson2025,
author = {Nelson, B E and Naing, A and Fu, S and Sheth, R A and Murthy, R and Piha-Paul, S},
title = {Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics},
journal = {Immuno-Oncology and Technology},
year = {2025},
volume = {25},
pages = {101040},
doi = {10.1016/j.iotech.2024.101040}
}
EUVIMED